BindingDB logo
myBDB logout

23 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28111141 58 The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics.EBI Merck& Co. Inc.
28105264 6 Potential of Renal Outer Medullary Potassium (ROMK) Channel as Treatments for Hypertension and Heart Failure.EBI Therachem Research Medilab (India) Pvt. Ltd.
27839686 65 Discovery of a potent and selective ROMK inhibitor with improved pharmacokinetic properties based on an octahydropyrazino[2,1-c][1,4]oxazine scaffold.EBI Merck Research Laboratories
27190590 11 Inhibitors of Renal Outer Medullary Potassium Channel.EBI Temple University
27017115 77 Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.EBI Merck Research Laboratories
26288678 12 Inhibitors of the Renal Outer Medullary Potassium Channel.EBI Temple University School of Pharmacy
26191360 99 Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.EBI Merck Research Laboratories
24075732 43 Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.EBI Merck Research Laboratories
24900480 75 Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.EBI TBA
15131245 86 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.BDB Sanofi-Synthelabo Recherche
9454810 72 SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB Sanofi Recherche